Posted in | Dendrimers | Nanobusiness

Starpharma Announces Key VivaGel Patent Approved in Japan

Starpharma Holdings Limited, a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications, today announced that one of its key patents relating to the use of dendrimers to protect against sexually transmitted infections has been approved in Japan.

This approval means that VivaGel® and the VivaGel® coated condom are now covered by granted patents in all major markets including Europe, the US and Japan.

Last month Starpharma announced a full licence agreement with SSL International plc (LSE:SSL) in relation to the VivaGel® coated condom, with estimated receipts in excess of A$100m comprising royalties, milestone payments and development support. In addition Starpharma is continuing to develop VivaGel® as a stand-alone product for use by women to protect themselves from HIV and HSV-2 (genital herpes). The development for these two indications has significant NIH support.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Starpharma Holdings Ltd. (2019, March 19). Starpharma Announces Key VivaGel Patent Approved in Japan. AZoNano. Retrieved on July 16, 2019 from https://www.azonano.com/news.aspx?newsID=8410.

  • MLA

    Starpharma Holdings Ltd. "Starpharma Announces Key VivaGel Patent Approved in Japan". AZoNano. 16 July 2019. <https://www.azonano.com/news.aspx?newsID=8410>.

  • Chicago

    Starpharma Holdings Ltd. "Starpharma Announces Key VivaGel Patent Approved in Japan". AZoNano. https://www.azonano.com/news.aspx?newsID=8410. (accessed July 16, 2019).

  • Harvard

    Starpharma Holdings Ltd. 2019. Starpharma Announces Key VivaGel Patent Approved in Japan. AZoNano, viewed 16 July 2019, https://www.azonano.com/news.aspx?newsID=8410.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit